#actelion

Massachusetts News: BOSTON, Actelion Pharmaceuticals Agrees to Pay $360 Million to Resolve Allegations that it Paid Kickbacks Through a Co-Pay Assistance Foundation

BOSTON, Ms. – The U.S. Attorney’s Office announced today that pharmaceutical company Actelion Pharmaceuticals US, Inc. (Actelion), a seller of pulmonary arterial hypertension (PAH) drugs, has agreed to pay $360 million to resolve allegations that it violated the False Claims Act by paying kickbacks to Medicare patients through a purportedly independent charitable foundation.

When a Medicare…

The U.S. FDA Designates Johnson & Johnson’s Cadazolid An Orphan Drug For Treatment of C.diff. Infection in Pediatric Patients

The FDA designates Johnson & Johnson’s

cadazolid an Orphan Drug for the treatment of

Clostridium difficile (C. diff) infection

in pediatric patients.

    Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

Cadazolid is a quinoxolidinone antibiotic being developed by Actelion.

        Source:

Aug. 9, 2017 7:40 AM…

Top Pharma News | May – June 2017

AstraZeneca’s Imfinzi (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer

01 May 2017

AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab). Imfinzi is indicated for the treatment of patients…

ZURICH (Reuters) - Swiss drugmaker Actelion's 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH), it said on Tuesday.

Johnson & Johnson to Purchase Actelion for $30 Billion

Jan 26, 2017

Johnson & Johnson (J&J) has said that it is going to buy Swiss biotech Actelion Pharmaceuticals for $30 billion. The company also plans to spin out its research and development unit into a separate business. The deal is expected to close in mid-February.

The companies said in a statement that J&J will pay $280 per share for the Allschwil, Switzerland-based group, which is the Swiss…